{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:24:18Z","timestamp":1791563058366,"version":"4.3.4"},"reference-count":131,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.vaccine.2023.01.053","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T12:16:47Z","timestamp":1702469807000},"page":"S42-S69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"S1","title":["Vaccine value profile for Neisseria gonorrhoeae"],"prefix":"10.1016","volume":"42","author":[{"given":"Yiming","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Choong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.F.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate L.","family":"Seib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen S.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Unemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"de Voux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica E.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami L.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve B.","family":"Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Wi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Baggaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laith J.","family":"Abu-Raddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston E.","family":"Abara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5784-7403","authenticated-orcid":false,"given":"Jason J.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.01.053_b0005","unstructured":"World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections. https:\/\/www.who.int\/publications\/i\/item\/9789240027077."},{"key":"10.1016\/j.vaccine.2023.01.053_b0010","article-title":"Global burden and trends of sexually transmitted infections from 1990 to 2019: an observational trend study","author":"Zheng","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2023.01.053_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(21)00171-3","article-title":"WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017\u201318: a retrospective observational study","volume":"2","author":"Unemo","year":"2021","journal-title":"Lancet Microbe"},{"issue":"10102","key":"10.1016\/j.vaccine.2023.01.053_b0020","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study","volume":"390","author":"Petousis-Harris","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.01.053_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00812-4","article-title":"Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study","author":"Abara","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.053_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00754-4","article-title":"Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study","author":"Wang","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.053_b0035","unstructured":"World Health Organization. WHO preferred product characteristics for gonococcal vaccines. https:\/\/www.who.int\/publications\/i\/item\/9789240039827."},{"issue":"28","key":"10.1016\/j.vaccine.2023.01.053_b0040","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1016\/j.vaccine.2020.02.073","article-title":"Gonococcal vaccines: public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019","volume":"38","author":"Gottlieb","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.053_b0045","unstructured":"World Health Organization. Global health sector strategy on sexually transmitted infections, 2016-2021. https:\/\/www.who.int\/publications\/i\/item\/WHO-RHR-16.09."},{"issue":"5","key":"10.1016\/j.vaccine.2023.01.053_b0050","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1071\/SH18097","article-title":"Gonorrhoea gone wild: rising incidence of gonorrhoea and associated risk factors among gay and bisexual men attending Australian sexual health clinics","volume":"16","author":"Callander","year":"2018","journal-title":"Sexual Health"},{"issue":"5","key":"10.1016\/j.vaccine.2023.01.053_b0055","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1071\/SH19027","article-title":"Risk factors for urethral gonorrhoea infection among heterosexual males in Melbourne, Australia: 2007\u201317","volume":"16","author":"Phillips","year":"2019","journal-title":"Sexual Health"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.053_b0060","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41572-019-0128-6","article-title":"Gonorrhoea","volume":"5","author":"Unemo","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.vaccine.2023.01.053_b0065","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1071\/SH19061","article-title":"Epidemiology of gonorrhoea: a global perspective","volume":"16","author":"Kirkcaldy","year":"2019","journal-title":"Sex Health"},{"issue":"4","key":"10.1016\/j.vaccine.2023.01.053_b0070","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1080\/13691058.2012.763187","article-title":"\u2018We are despised in the hospitals\u2019: sex workers' experiences of accessing health care in four African countries","volume":"15","author":"Scorgie","year":"2013","journal-title":"Cult Health Sex"},{"issue":"3","key":"10.1016\/j.vaccine.2023.01.053_b0075","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/sti.2010.047514","article-title":"Prevalence of sexually transmitted co-infections in people living with HIV\/AIDS: systematic review with implications for using HIV treatments for prevention","volume":"87","author":"Kalichman","year":"2011","journal-title":"Sex Transm Infect"},{"issue":"12","key":"10.1016\/j.vaccine.2023.01.053_b0080","doi-asserted-by":"crossref","DOI":"10.1097\/OLQ.0b013e31818d3cad","article-title":"Social determinants and sexually transmitted disease disparities","volume":"35","author":"Hogben","year":"2008","journal-title":"Sex Transm Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.053_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-021-06381-4","article-title":"Gonorrhoea: a systematic review of prevalence reporting globally","volume":"21","author":"Whelan","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2023.01.053_b0090","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/OLQ.0000000000001355","article-title":"Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2018","volume":"48","author":"Kreisel","year":"2021","journal-title":"Sex Transm Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2023.01.053_b0095","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/jama.2021.14081","article-title":"Screening for chlamydia and gonorrhea: US Preventive Services Task Force recommendation statement","volume":"326","author":"Davidson","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.053_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169388","article-title":"Barriers and facilitators of screening for sexually transmitted infections in adolescent girls and young women in Mombasa, Kenya: a qualitative study","volume":"12","author":"Avuvika","year":"2017","journal-title":"PloS one"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.053_b0105","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/jamainternmed.2015.4683","article-title":"Preexposure prophylaxis for HIV infection integrated with municipal-and community-based sexual health services","volume":"176","author":"Liu","year":"2016","journal-title":"JAMA Int Med"},{"key":"10.1016\/j.vaccine.2023.01.053_b0110","unstructured":"Centers for Disease Control and Prevention. Sexually transmitted disease surveillance. In 2021 U.S. Department of Health and Human Services Atlanta; 2019."},{"issue":"6","key":"10.1016\/j.vaccine.2023.01.053_b0115","doi-asserted-by":"crossref","first-page":"e005191","DOI":"10.1136\/bmjopen-2014-005191","article-title":"Criminalisation of clients: reproducing vulnerabilities for violence and poor health among street-based sex workers in Canada\u2014a qualitative study","volume":"4","author":"Kr\u00fcsi","year":"2014","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.053_b0120","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3201\/eid2201.151331","article-title":"Increase in sexually transmitted infections among men who have sex with men, England, 2014","volume":"22","author":"Mohammed","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.053_b0125","series-title":"Sexually transmitted infections and screening for chlamydia in England, 2019","author":"Mitchell","year":"2020"},{"key":"10.1016\/j.vaccine.2023.01.053_b0130","unstructured":"Control ECfDPa. Gonorrhoea \u2013 annual epidemiological report for 2017. In Stockholm: ECDC; 2019."},{"key":"10.1016\/j.vaccine.2023.01.053_b0135","unstructured":"Northern Territory Department of Health Surveillance update for notifiable sexually transmitted infections and blood-borne viruses in the northern territory. In vol. 22; 2021."},{"issue":"12","key":"10.1016\/j.vaccine.2023.01.053_b0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260063","article-title":"The worldwide burden of HIV in transgender individuals: an updated systematic review and meta-analysis","volume":"16","author":"Stutterheim","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.01.053_b0145","doi-asserted-by":"crossref","DOI":"10.26633\/RPSP.2019.17","article-title":"HIV, syphilis, and viral hepatitis among Latin American indigenous peoples and Afro-descendants: a systematic review","volume":"43","author":"Russell","year":"2019","journal-title":"Rev Panam Salud Publica"},{"issue":"2","key":"10.1016\/j.vaccine.2023.01.053_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002511","article-title":"Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: an individual participant data meta-analysis of 18 HIV prevention studies","volume":"15","author":"Torrone","year":"2018","journal-title":"PLoS Med"},{"issue":"8","key":"10.1016\/j.vaccine.2023.01.053_b0155","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.2105\/AJPH.2014.302044","article-title":"Mortality from sexually transmitted diseases in reproductive-aged women: United States, 1999\u20132010","volume":"104","author":"McElligott","year":"2014","journal-title":"Am J Pub Health"},{"issue":"10258","key":"10.1016\/j.vaccine.2023.01.053_b0160","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Vos","year":"2020","journal-title":"The Lancet"},{"issue":"50","key":"10.1016\/j.vaccine.2023.01.053_b0165","doi-asserted-by":"crossref","first-page":"7419","DOI":"10.1016\/j.vaccine.2018.02.081","article-title":"Biological feasibility and importance of a gonorrhea vaccine for global public health","volume":"37","author":"Vincent","year":"2019","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2023.01.053_b0170","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1071\/SH19060","article-title":"Advancing vaccine development for gonorrhoea and the Global STI Vaccine Roadmap","volume":"16","author":"Gottlieb","year":"2019","journal-title":"Sexual Health"},{"issue":"4","key":"10.1016\/j.vaccine.2023.01.053_b0175","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1007\/s40121-021-00481-z","article-title":"Systematic literature review and quantitative analysis of health problems associated with sexually transmitted Neisseria gonorrhoeae infection","volume":"10","author":"Whelan","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2023.01.053_b0180","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/sextrans-2020-054653","article-title":"Adverse pregnancy and neonatal outcomes associated with Neisseria gonorrhoeae: systematic review and meta-analysis","volume":"97","author":"Vallely","year":"2021","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2023.01.053_b0185","first-page":"12","article-title":"Infertility: a global perspective. The role of pelvic infection","volume":"3","author":"Sciarra","year":"1994","journal-title":"ORGYN"},{"key":"10.1016\/j.vaccine.2023.01.053_b0190","unstructured":"World Health Organization. Report on global sexually transmitted infection surveillance; 2018."},{"issue":"6","key":"10.1016\/j.vaccine.2023.01.053_b0195","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1071\/SH16122","article-title":"Seasonal variation in gonorrhoea incidence among men who have sex with men","volume":"13","author":"Li","year":"2016","journal-title":"Sex Health"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.053_b0200","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1083-3188(00)00079-6","article-title":"Is there a seasonal variation in gonorrhea and chlamydia in adolescents?","volume":"14","author":"Schroeder","year":"2001","journal-title":"J Ped Adol Gynecol"},{"key":"10.1016\/j.vaccine.2023.01.053_b0205","article-title":"Australian gonococcal surveillance programme annual report, 2020","volume":"vol. 45","author":"Lahra","year":"2021","journal-title":"Commun Dis Intell"},{"key":"10.1016\/j.vaccine.2023.01.053_b0210","unstructured":"Science for Communities. Sexually Transmitted Infection (STI) surviellance (dashboard). https:\/\/www.esr.cri.nz\/our-services\/consultancy\/public-health\/sti\/."},{"issue":"5","key":"10.1016\/j.vaccine.2023.01.053_b0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196516","article-title":"Population-based study of chlamydial and gonococcal infections among women in Shenzhen, China: implications for programme planning","volume":"13","author":"Luo","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2023.01.053_b0220","unstructured":"Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2020. In Atlanta: US Department of Health and Human Services; 2022."},{"issue":"8","key":"10.1016\/j.vaccine.2023.01.053_b0225","doi-asserted-by":"crossref","first-page":"548","DOI":"10.2471\/BLT.18.228486","article-title":"Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016","volume":"97","author":"Rowley","year":"2019","journal-title":"Bull World Health Org"},{"issue":"7","key":"10.1016\/j.vaccine.2023.01.053_b0230","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/OLQ.0b013e31829529cf","article-title":"Socioeconomic disparities in sexually transmitted infections among young adults in the United States: examining the interaction between income and race\/ethnicity","volume":"40","author":"Harling","year":"2013","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2023.01.053_b0235","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3389\/fimmu.2020.01375","article-title":"Immunity to Neisseria gonorrhoeae","volume":"11","author":"Russell","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.01.053_b0240","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fmicb.2011.00124","article-title":"Vaccines for gonorrhea: can we rise to the challenge?","volume":"2","author":"Zhu","year":"2011","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2023.01.053_b0245","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.3389\/fimmu.2018.03187","article-title":"Human immune responses and the natural history of Neisseria gonorrhoeae infection","volume":"9","author":"Lovett","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2023.01.053_b0250","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/sti.53.6.353","article-title":"Cell-mediated immune response in gonococcal infections","volume":"53","author":"Wyle","year":"1977","journal-title":"Sex Transm Infect"},{"issue":"6","key":"10.1016\/j.vaccine.2023.01.053_b0255","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3109\/1040841X.2015.1105782","article-title":"Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development","volume":"42","author":"Edwards","year":"2016","journal-title":"Criti Rev Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2023.01.053_b0260","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1128\/CMR.00040-10","article-title":"Review and international recommendation of methods for typing Neisseria gonorrhoeae isolates and their implications for improved knowledge of gonococcal epidemiology, treatment, and biology","volume":"24","author":"Unemo","year":"2011","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1016\/j.vaccine.2023.01.053_b0265","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/CMR.00010-14","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future","volume":"27","author":"Unemo","year":"2014","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"10.1016\/j.vaccine.2023.01.053_b0270","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1071\/SH19023","article-title":"World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts","volume":"16","author":"Unemo","year":"2019","journal-title":"Sex Health"},{"key":"10.1016\/j.vaccine.2023.01.053_b0275","doi-asserted-by":"crossref","unstructured":"Unemo M, Golparian D, Eyre DW. Antimicrobial resistance in Neisseria gonorrhoeae and treatment of gonorrhea. In Neisseria Gonorrhoeae. Springer; 2019. p. 37\u201358.","DOI":"10.1007\/978-1-4939-9496-0_3"},{"key":"10.1016\/j.vaccine.2023.01.053_b0280","unstructured":"Institute K. HIV, viral hepatitis and sexually transmissible infections in Australia: Annual surveillance report 2018. In Sydney: Kirby Institute, UNSW Sydney; 2018."},{"key":"10.1016\/j.vaccine.2023.01.053_b0285","first-page":"5657","article-title":"Trends in the epidemiology of sexually transmitted disease, acquired immune deficiency syndrome (AIDS), gonorrhea, and syphilis, in the 31 provinces of mainland China","volume":"25","author":"Ye","year":"2019","journal-title":"Med Sci Monitor Int Med J Exp Clin Res"},{"key":"10.1016\/j.vaccine.2023.01.053_b0290","unstructured":"Centers for Disease Control and Prevention. Gonorrhea detailed fact sheet: centers for disease control and prevention. https:\/\/www.cdc.gov\/std\/gonorrhea\/stdfact-gonorrhea-detailed.htm."},{"key":"10.1016\/j.vaccine.2023.01.053_b0295","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3389\/fimmu.2019.02417","article-title":"Progress toward a gonococcal vaccine: the way forward","author":"Russell","year":"2019","journal-title":"Front Immunol"},{"issue":"0 4","key":"10.1016\/j.vaccine.2023.01.053_b0300","article-title":"Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning?","volume":"24","author":"Hayes","year":"2010","journal-title":"AIDS (London, England)"},{"key":"10.1016\/j.vaccine.2023.01.053_b0305","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25355","article-title":"Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy","volume":"22","author":"Cohen","year":"2019","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.053_b0310","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/sti.2010.042879","article-title":"HIV infection and sexual behaviour in primary and secondary infertile relationships: a case\u2013control study in Kigali, Rwanda","volume":"87","author":"Dhont","year":"2011","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2023.01.053_b0315","article-title":"Pathogenesis of Neisseria gonorrhoeae and the host defense in ascending infections of human fallopian tube","volume":"2710","author":"Lenz","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.01.053_b0320","article-title":"Sexually transmitted infections: impact and cost-effectiveness of prevention","volume":"6","author":"Chesson","year":"2017","journal-title":"Dis Control Prior Major Inf Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2023.01.053_b0325","doi-asserted-by":"crossref","DOI":"10.1097\/OLQ.0000000000001240","article-title":"Estimating the direct medical costs and productivity loss of outpatient chlamydia and gonorrhea treatment","volume":"48","author":"Kumar","year":"2021","journal-title":"Sex Transm Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.053_b0330","doi-asserted-by":"crossref","first-page":"e0170773","DOI":"10.1371\/journal.pone.0170773","article-title":"Costing of national STI program implementation for the Global STI control strategy for the health sector, 2016\u20132021","volume":"12","author":"Korenromp","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.01.053_b0335","unstructured":"World Health Organization. The gonococcal antimicrobial surveillance programme (GASP). https:\/\/www.who.int\/initiatives\/gonococcal-antimicrobial-surveillance-programme."},{"key":"10.1016\/j.vaccine.2023.01.053_b0340","unstructured":"World Health Organization. Strategies and laboratory methods for strengthening surveillance of sexually transmitted infections 2012, http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/75729\/9789241504478_eng.pdf?sequence=1."},{"key":"10.1016\/j.vaccine.2023.01.053_b0345","unstructured":"World Health Organization. Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/85343\/9789241505840_eng.pdf."},{"key":"10.1016\/j.vaccine.2023.01.053_b0350","unstructured":"World Health Organization. WHO guidelines for the treatment of Neisseria gonorrhoeae https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/246114\/9789241549691-eng.pdf?sequence=1."},{"key":"10.1016\/j.vaccine.2023.01.053_b0355","doi-asserted-by":"crossref","unstructured":"Garrett NJ, McGrath N, Mindel A. Advancing STI care in low\/middle-income countries: has STI syndromic management reached its use-by date? In vol. 93: BMJ Publishing Group Ltd; 2017. p. 4\u20135.","DOI":"10.1136\/sextrans-2016-052581"},{"issue":"6","key":"10.1016\/j.vaccine.2023.01.053_b0360","first-page":"454","article-title":"Effectiveness of condoms in preventing sexually transmitted infections","volume":"82","author":"Holmes","year":"2004","journal-title":"Bull World Health Org"},{"issue":"8","key":"10.1016\/j.vaccine.2023.01.053_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(17)30310-9","article-title":"Sexually transmitted infections: challenges ahead","volume":"17","author":"Unemo","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.053_b0370","article-title":"European guideline for the diagnosis and treatment of gonorrhoea in adults","volume":"2020","author":"Unemo","year":"2020","journal-title":"Int J STD AIDS"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.053_b0375","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/0956462419886775","article-title":"2018 UK national guideline for the management of infection with Neisseria gonorrhoeae","volume":"31","author":"Fifer","year":"2020","journal-title":"Int J STD & AIDS"},{"issue":"50","key":"10.1016\/j.vaccine.2023.01.053_b0380","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.15585\/mmwr.mm6950a6","article-title":"Update to CDC's treatment guidelines for gonococcal infection, 2020","volume":"69","author":"St Cyr","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"25","key":"10.1016\/j.vaccine.2023.01.053_b0385","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMc1512757","article-title":"Failure of dual antimicrobial therapy in treatment of gonorrhea","volume":"374","author":"Fifer","year":"2016","journal-title":"New Eng J Med"},{"issue":"27","key":"10.1016\/j.vaccine.2023.01.053_b0390","doi-asserted-by":"crossref","first-page":"1800323","DOI":"10.2807\/1560-7917.ES.2018.23.27.1800323","article-title":"Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018","volume":"23","author":"Eyre","year":"2018","journal-title":"Eurosurveillance"},{"issue":"24","key":"10.1016\/j.vaccine.2023.01.053_b0395","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2022.27.24.2200455","article-title":"Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022","volume":"27","author":"Pleininger","year":"2022","journal-title":"Euro Surveill"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.053_b0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-020-09815-x","article-title":"Young women\u2019s autonomy and information needs in the schools-based HPV vaccination programme: a qualitative study","volume":"20","author":"Fisher","year":"2020","journal-title":"BMC Pub Health"},{"issue":"4","key":"10.1016\/j.vaccine.2023.01.053_b0405","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1753-6405.2009.00409.x","article-title":"Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia","volume":"33","author":"Watson","year":"2009","journal-title":"Aust N Z J Pub Health"},{"issue":"36","key":"10.1016\/j.vaccine.2023.01.053_b0410","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1016\/j.vaccine.2015.07.015","article-title":"The potential impact of vaccination on the prevalence of gonorrhea","volume":"33","author":"Craig","year":"2015","journal-title":"Vaccine"},{"issue":"25","key":"10.1016\/j.vaccine.2023.01.053_b0415","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","article-title":"Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles\u2013mumps\u2013rubella\u2013varicella vaccine during the second year of life: an open, randomized controlled trial","volume":"29","author":"Vesikari","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.053_b0420","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2471\/BLT.09.068213","article-title":"Behavioural interventions for HIV positive prevention in developing countries: a systematic review and meta-analysis","volume":"88","author":"Kennedy","year":"2010","journal-title":"Bull World Health Org"},{"key":"10.1016\/j.vaccine.2023.01.053_b0425","series-title":"Prevention and treatment of HIV and other sexually transmitted infections for sex workers in low-and middle-income countries: recommendations for a public health approach","author":"World Health Organization","year":"2012"},{"issue":"3","key":"10.1016\/j.vaccine.2023.01.053_b0430","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s10461-019-02453-4","article-title":"Barriers to accessing sexual health services for transgender and male sex workers: a systematic qualitative meta-summary","volume":"24","author":"Brookfield","year":"2020","journal-title":"AIDS Behavior"},{"key":"10.1016\/j.vaccine.2023.01.053_b0435","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/953123","article-title":"Access to basic HIV-related services and PrEP acceptability among men who have sex with men worldwide: barriers, facilitators, and implications for combination prevention","author":"Ayala","year":"2013","journal-title":"J Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2023.01.053_b0440","first-page":"1","article-title":"Social media use in 2021","volume":"1","author":"Auxier","year":"2021","journal-title":"Pew Res Center"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.053_b0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6963-11-79","article-title":"Utilisation of sexual health services by female sex workers in Nepal","volume":"11","author":"Ghimire","year":"2011","journal-title":"BMC Health Serv Res"},{"issue":"35","key":"10.1016\/j.vaccine.2023.01.053_b0450","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1016\/j.vaccine.2019.07.014","article-title":"Vaccinations in prison settings: a systematic review to assess the situation in EU\/EEA countries and in other high income countries","volume":"37","author":"Madeddu","year":"2019","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2023.01.053_b0455","doi-asserted-by":"crossref","first-page":"7589","DOI":"10.3390\/ijerph17207589","article-title":"Vaccination coverage among prisoners: a systematic review","volume":"17","author":"Vicente-Alcalde","year":"2020","journal-title":"Int J Environ Res Pub Health"},{"key":"10.1016\/j.vaccine.2023.01.053_b0460","unstructured":"National Aboriginal and Torres Strait Islander Blood Borne Viruses and Sexually Transmissible Infections Strategy 2018\u20132022. In 2018."},{"key":"10.1016\/j.vaccine.2023.01.053_b0465","unstructured":"World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed. In Geneva; 2017 https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed."},{"key":"10.1016\/j.vaccine.2023.01.053_b0470","unstructured":"World Health Organization. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae; 2012."},{"key":"10.1016\/j.vaccine.2023.01.053_b0475","unstructured":"World Health Organization. Global HIV, Hepatitis and STIs Programmes. Global health sector strategies 2022\u20132030. https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/strategies\/global-health-sector-strategies."},{"key":"10.1016\/j.vaccine.2023.01.053_b0480","unstructured":"Neisseria gonorrhoeae Antimicrobial Resistance Surveillance: Consolidated Guidance. In Washington, D.C: Pan American Health Organization; 2020."},{"key":"10.1016\/j.vaccine.2023.01.053_b0485","unstructured":"The Boston Consulting Group. Vaccines to tackle drug resistant infections. An evaluation of R&D opportunities. https:\/\/vaccinesforamr.org\/."},{"key":"10.1016\/j.vaccine.2023.01.053_b0490","unstructured":"European Centre for Disease Prevention Control. Response plan to control and manage the threat of multidrug-resistant gonorrhoea in Europe. In 2012."},{"issue":"18","key":"10.1016\/j.vaccine.2023.01.053_b0495","doi-asserted-by":"crossref","first-page":"2100611","DOI":"10.2807\/1560-7917.ES.2022.27.18.2100611","article-title":"The European response to control and manage multi-and extensively drug-resistant Neisseria gonorrhoeae","volume":"27","author":"Cole","year":"2022","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.vaccine.2023.01.053_b0500","unstructured":"Centers for Disease Control Prevention. National strategy for combating antibiotic-resistant bacteria. Antibiotic Resistance Treats in the United States; 2013."},{"key":"10.1016\/j.vaccine.2023.01.053_b0505","unstructured":"Federal Task Force on Combating Antibiotic-Resistant Bacteria. National action plan for combating antibiotic-resistant bacteria, 2020\u20132025; 2020."},{"issue":"8","key":"10.1016\/j.vaccine.2023.01.053_b0510","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1128\/CVI.00230-16","article-title":"Summary and recommendations from the national institute of allergy and infectious diseases (NIAID) workshop \u201cgonorrhea vaccines: the way forward\u201d","volume":"23","author":"Wetzler","year":"2016","journal-title":"Clin Vacc Immunol"},{"key":"10.1016\/j.vaccine.2023.01.053_b0515","unstructured":"Neisseria gonorrhoeae antimicrobial resistance surveillance in Gauteng province, South Africa. Commun Dis Surveill Bull 2018;14(3):56\u201364."},{"key":"10.1016\/j.vaccine.2023.01.053_b0520","unstructured":"Australia\u2019s National Antimicrobial Resistance Strategy\u20102020 and Beyond. In.: Australian Government. Department of Health and Department of Agriculture, Water and the Enviroment; 2020."},{"key":"10.1016\/j.vaccine.2023.01.053_b0525","unstructured":"Australian Government Department of Health. National Blood Borne Viruses and Sexually Transmissible Infections Research Strategy 2021\u20132025 In.."},{"issue":"26","key":"10.1016\/j.vaccine.2023.01.053_b0530","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.vaccine.2016.03.111","article-title":"The global roadmap for advancing development of vaccines against sexually transmitted infections: update and next steps","volume":"34","author":"Gottlieb","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.053_b0800","unstructured":"Assessing the programmatic suitability of vaccine candidates for WHO prequalification. Geneva: World Health Organization; 2014 (WHO\/IVB\/12.10; https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/148168\/WHO_IVB_14.10_eng.pdf."},{"key":"10.1016\/j.vaccine.2023.01.053_b0540","unstructured":"Safety and efficacy study of meningococcal group B Vaccine rMenB\u00a0+\u00a0OMV NZ (Bexsero) to prevent gonococcal infection; 2020. In https:\/\/ClinicalTrials.gov\/show\/NCT04350138."},{"issue":"14","key":"10.1016\/j.vaccine.2023.01.053_b0545","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.vaccine.2013.08.067","article-title":"Vaccines against gonorrhea: current status and future challenges","volume":"32","author":"Jerse","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.053_b0550","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25343","article-title":"Diagnosing sexually transmitted infections in resource-constrained settings: challenges and ways forward","volume":"22","author":"Wi","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.vaccine.2023.01.053_b0555","doi-asserted-by":"crossref","unstructured":"Semchenko EA, Jen FE-C, Jennings MP, Seib KL. Assessment of serum bactericidal and opsonophagocytic activity of antibodies to gonococcal vaccine Targets. In Bacterial vaccines. Springer; 2022. P. 363\u201372.","DOI":"10.1007\/978-1-0716-1900-1_19"},{"issue":"6","key":"10.1016\/j.vaccine.2023.01.053_b0560","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02552-19","article-title":"Preclinical efficacy of a lipooligosaccharide peptide mimic candidate gonococcal vaccine","volume":"10","author":"Gulati","year":"2019","journal-title":"MBio"},{"issue":"137","key":"10.1016\/j.vaccine.2023.01.053_b0565","article-title":"The Neisseria gonorrhoeae methionine sulfoxide reductase (MsrA\/B) is a surface exposed, immunogenic, vaccine candidate","volume":"10","author":"Jen","year":"2019","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2023.01.053_b0570","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/cid\/ciy1061","article-title":"The serogroup B meningococcal vaccine bexsero elicits antibodies to Neisseria gonorrhoeae","volume":"69","author":"Semchenko","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.053_b0575","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fmicb.2011.00123","article-title":"Experimental gonococcal infection in male volunteers: cumulative experience with Neisseria gonorrhoeae strains FA1090 and MS11mkC","volume":"2","author":"Hobbs","year":"2011","journal-title":"Frontiers in Microbiology"},{"key":"10.1016\/j.vaccine.2023.01.053_b0580","doi-asserted-by":"crossref","unstructured":"Waltmann A, Duncan JA, Pier GB, Cywes-Bentley C, Cohen MS, Hobbs MM. Experimental urethral infection with Neisseria gonorrhoeae. In Springer; 2022.","DOI":"10.1007\/82_2021_250"},{"key":"10.1016\/j.vaccine.2023.01.053_b0585","unstructured":"Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine. In https:\/\/ClinicalTrials.gov\/show\/NCT04094883."},{"key":"10.1016\/j.vaccine.2023.01.053_b0590","unstructured":"WHO Expert Committee on Biological Standardization. Meeting World Health Organization. Expert Committee on Biological Standardization. WHO Expert Committee on Biological Standardization: Sixty-first Report, vol. 978. World Health Organization; 2013."},{"issue":"2","key":"10.1016\/j.vaccine.2023.01.053_b0595","article-title":"An observational study to assess the effectiveness of 4CMenB against meningococcal disease and carriage and gonorrhea in adolescents in the Northern territory, Australia-study protocol","volume":"10","author":"Marshall","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.01.053_b0600","unstructured":"Efficacy Study of 4CMenB (Bexsero\u00ae) to Prevent Gonorrhoea Infection in Gay and Bisexual Men; 2021. In https:\/\/ClinicalTrials.gov\/show\/NCT04415424."},{"key":"10.1016\/j.vaccine.2023.01.053_b0605","unstructured":"Combined Prevention of Sexually Transmitted Infections (STIs) in Men who have sex with Men and Using Oral Tenofovir Disoproxil Fumarate\/Emtricitabine (TDF\/FTC) for HIV Pre-Exposure Prophylaxis (PrEP) (DOXYVAC); 2021. In https:\/\/clinicaltrials.gov\/study\/NCT04597424."},{"key":"10.1016\/j.vaccine.2023.01.053_b0610","unstructured":"MenGO: Does the licensed meningococcal vaccine Bexsero\u00ae provide cross- protection against gonorrhoea; 2019? In https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=376715."},{"key":"10.1016\/j.vaccine.2023.01.053_b0615","unstructured":"National Institute of Allergy Infectious Diseases. Mucosal immunity against Neisseria gonorrhoeae after 4CMenB vaccination; 2021. In https:\/\/ClinicalTrials.gov\/show\/NCT04722003."},{"key":"10.1016\/j.vaccine.2023.01.053_b0620","unstructured":"Safety and Efficacy of GSK Neisseria gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age; 2022. In https:\/\/clinicaltrials.gov\/study\/NCT05630859."},{"key":"10.1016\/j.vaccine.2023.01.053_b0625","unstructured":"Wang B. Vaccine effectiveness and impact of 4CMenB against meningococcal B disease and gonorrhoea. In Communicable Diseases and immunisation conference. Sydney; 21st June 2022."},{"issue":"12","key":"10.1016\/j.vaccine.2023.01.053_b0630","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.4161\/hv.36221","article-title":"Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model","volume":"10","author":"R\u00e9gnier","year":"2014","journal-title":"Hum Vacc Immunother"},{"issue":"8","key":"10.1016\/j.vaccine.2023.01.053_b0635","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1093\/cid\/ciz1241","article-title":"Assessment of the potential of vaccination to combat antibiotic resistance in gonorrhea: a modeling analysis to determine preferred product characteristics","volume":"71","author":"Whittles","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.053_b0640","doi-asserted-by":"crossref","unstructured":"Heijne JC, Xiridou M, Turner KM, Basten M, Visser M, van Benthem B, Low N. The impact of vaccination on Neisseria gonorrhoeae antimicrobial resistance and prevalence in men who have sex with men: a mathematical modelling study. MedRxiv; 2020.","DOI":"10.1101\/2020.09.14.20192062"},{"issue":"6","key":"10.1016\/j.vaccine.2023.01.053_b0645","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/infdis\/jiab581","article-title":"A gonococcal vaccine has the potential to rapidly reduce the incidence of Neisseria gonorrhoeae infection among urban men who have sex with men","volume":"225","author":"Hui","year":"2022","journal-title":"J infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2023.01.053_b9000","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S1473-3099(21)00744-1","article-title":"Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis","volume":"22","author":"Whittles","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2023.01.053_b9001","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/OLQ.0000000000000725","article-title":"An illustration of the potential health and economic benefits of combating antibiotic-resistant gonorrhea","volume":"45","author":"Chesson","year":"2018","journal-title":"Sex Transm Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T12:46:43Z","timestamp":1726058803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23000865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":131,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0264410X23000865"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.053","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine value profile for Neisseria gonorrhoeae","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}